Differential Plasma Phosphoproteomes with *Opisthorchis viverrini*-Related Cholangiocarcinomas

Kanawut Kotawong¹², Veerachai Thitapakorn¹², Sittiruk Roytrakul³, Narumon Phaonakrop³, Vithoon Viyanant¹², Kesara Na-Bangchang¹²,⁴*

Abstract

This study was conducted to investigate the plasma phosphoproteome and differential plasma phosphoproteins in cases of *Opisthorchis viverrini* (OV)-related cholangiocarcinoma (CCA). Plasma phosphoproteomes from CCA patients (10) and non-CCA subjects (5 each for healthy subjects and OV infection) were investigated using gel-based and solution-based LC-MS/MS. Phosphoproteins in plasma samples were enriched and analyzed by LC-MS/MS. STRAP, PANTHER, iPath, and MeV programs were applied for the identification of their functions, signaling and metabolic pathways; and for the discrimination of potential biomarkers in CCA patients and non-CCA subjects, respectively. A total of 90 and 60 plasma phosphoproteins were identified by gel-based and solution-based LC-MS/MS, respectively. Most of the phosphoproteins were cytosol proteins which play roles in several cellular processes, signaling pathways, and metabolic pathways (STRAP, PANTHER, and iPath analysis). The absence of serine/arginine repetitive matrix protein 3 (A6NNA2), tubulin tyrosine ligase-like family, member 6, and biorientation of chromosomes in cell division protein 1-like (Q8NFC6) in plasma phosphoprotein were identified as potential biomarkers for the differentiation of healthy subjects from patients with CCA and OV infection. To differentiate CCA from OV infection, the absence of both serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit beta isoform and coiled-coil domain-containing protein 126 precursor (Q96EE4) were then applied. A combination of 5 phosphoproteins may new alternative choices for CCA diagnosis.

Keywords: Biomarkers - cholangiocarcinoma - LC-MS/MS - phosphoproteomes
et al., 2014). Information on the proteome of CCA plasma particularly phosphoproteins could be exploited for therapeutic, diagnostic, and prognostic applications. Furthermore, it also provides essential basic knowledge at the molecular level especially with regard to cell signaling, proliferation, and differentiation, which would lead to the target discovery of anti-CCA drugs. The proteomics of a number of human cells have been investigated using high-throughput liquid chromatography mass-spectrometry (LC-MS/MS) (Srisomsap et al., 2010; White et al., 2014). The aim of this study was to investigate plasma phosphoproteome and identify potential biomarkers for the diagnosis of patients with OV-related CCA. Serum phosphoproteome profiles have been demonstrated as potential markers for diagnosis and prognosis of pancreatic cancer (Li et al., 2013), esophageal squamous cell carcinoma (Wan et al., 2013), and colorectal cancer (Deng et al., 2013). Here, bioinformatics approaches were applied to analyze the phosphoproteome and the potential biomarker to discriminate CCA patient from OV infected patient and healthy subjects.

Materials and Methods

Plasma samples and enrichment of plasma phosphoproteins.

Plasma samples obtained from 10 CCA patients (8 males and 2 females, aged 36-72 years) and 10 non-CCA subjects (5 each for healthy subjects and patients with OV infection); 9 males and 1 female, aged 32-63 years) were kindly provided by Dr. Petcharin Srivatanakul of the National Cancer Institute of Thailand. Ethical approval of the study protocol was obtained from the Ethics Committee of the Ministry of Public Health of Thailand. Written informed consent for study participation was obtained from all subjects prior to the study. The diagnosis of CCA was based on ultrasonography, laboratory [tumor markers (alpha-fetoprotein: AFP, CA19-9) and liver function tests (AST, ALT, ALP)], and histopathological examinations. Alpha-1-antitrypsin (AP1), the candidate biomarker of CCA was also included (Sriwanitchar et al., 2011). Plasma protein concentrations were determined using Lowry’s method, and protein concentration of albumin (SIGMA-Aldrich, MO, USA) as a reference standard (Lowry et al., 1951). Protein concentration of each sample was adjusted to a final concentration of 10 µg/µl and subjected to phosphoprotein enrichment procedure (Phosphoprotein Enrichment Kit, Pierce, IL, USA). The enriched phosphoprotein was concentrated using 9 kDa cut-off membrane column (Phosphoprotein Enrichment Kit, Pierce, IL, USA) and desalted by gel filtration (Thermo Scientific, Rockford, IL, USA). Protein concentration was determined using Lowry’s method, and molecular size was determined using 12.5% SDS-PAGE (Figure 1A).

Analysis of enriched plasma phosphoproteins by LC-MS/MS

Enriched plasma phosphoproteins from samples obtained from the CCA patients and non-CCA subjects were investigated using two different techniques, i.e., gel-based and solution-based LC-MS/MS. Gel-based LC-MS/MS: Enriched plasma phosphoproteins from both groups of subjects were initially separated based on molecular size using 12.5% SDS-PAGE. The patterns and intensity of separated proteins from plasma of both groups of subjects were generally similar, with difference in intensity only for proteins separated at the molecular size of 14-21 kDa (Figure 1A). The samples from three subjects of each group were therefore, further resolved by two dimensional gel electrophoresis (2DE) using ReadyStrip™ IPG Strip (Bio-Rad, OR, USA). The prominent up-regulated protein spots were cut and washed with sterile water. Following incubation with 100% acetonitrile, the spots were left dried at room temperature for 5 min, followed by carbamidomethylation with buffer I (10 mM each of dithiothreitol and ammonium bicarbonate) and buffer II (100 mM iodoacetamide and 10 mM ammonium bicarbonate) at room temperature for 1 hour each. The spots were digested with trypsin (10 ng trypsin in 50% acetonitrile/10 mM ammonium bicarbonate) for 12 hours, and extracted with three times with 50% acetonitrile. The extracts were pooled, concentrated (40°C for 12 hours), and dissolved with 0.1% formic acid. The digested extracts were injected into a µ-precolumn (Monolithic Trap Column: 200 µm, 5 mm i.d., Amsterdam, Netherlands) coupled with the Ultimate 3000 LC system (Dionex, Bremen, Germany) and ESI-Ion Trap MS (HCT ultra PTM Discovery System, BrukerDaltonik, Bremen, Germany) with electrospray at a flow rate of 20µl/min. Proteins were separated on a nano-column (Monolithic NanoColumn: 100 µm, 5 mm i.d., Amsterdam, Netherlands) with a solvent gradient mobile phase consisting of solvent A (0.1% formic acid) and solvent B (50% water, 50% acetonitrile, and 0.1% formic acid) running at a flow rate of 1 µl/min with 20 min run time.

Solution-based LC-MS/MS: Solution-based LC-MS/MS analysis was performed for the enriched plasma phosphoprotein samples from both groups of subjects using 50 µg proteins prepared as previously described for the gel-based LC-MS/MS with modification. The enriched plasma phosphoprotein was treated with buffer I and buffer II for 1 hour each. Buffer I was then added and incubated for an additional 1 hour to inhibit the carbamidomethyl reaction. For digestion, a mixture of 10 ng trypsin in 50% acetonitrile and 10 mM ammonium bicarbonate was added into the solution and incubated overnight at room temperature. Finally, protein solution was injected into LC-MS/MS.

Analysis of LC-MS/MS data

The obtained LC-MS/MS data from both methods (gel-based and solution-based LC-MS/MS) were analyzed by using the DeCyder MSTM program (Amersham Bioscience AB, Uppsala, Sweden) and MASCOT (http://www.matrixscience.com). To exclude co-purified non-phosphoproteins, PhosphoSitePlus was applied for the phosphorylation site analysis (http://www.phosphosite.org). Gene ontology, signaling pathways, and metabolic pathways were analyzed by using STRAP (Vivek Bhatia, Boston University School of Medicine), PANTHER (http://www.pantherdb.org) (Mi et al., 2013), and iPath.
Differential Plasma Phosphoproteomes with *Opisthorchis viverrini*-Related Cholangiocarcinomas

Figure 1. (A) The 12.5% SDS-PAGE and (B) 2DE of Phosphoproteins of Plasma Samples from CCA Patients and Non-CCA Subjects (10 each)

Data analysis

Comparison of the clinical laboratory data between samples from CCA patients and non-CCA subjects was performed using Mann-Whitney U test at a statistical significance level of α=0.05. The performance of the diagnostic tests (laboratory tests and potential biomarkers) to discriminate between CCA patients and non-CCA subjects included AUC—the area under the curve of the receiver-operating characteristic (ROC) curve for diagnostic accuracy (SPSS version 15, NY, USA). The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of potential phosphoproteins were calculated using DAG-STAT (Mackinnon, 2000).

Results

Subjects and phosphoprotein preparation

The concentrations of the liver enzymes ALP and AST, and AP1 of the samples from CCA patients were significantly higher than those from non-CCA subjects [median (range): 316 (171-1,047) vs 80 (44-98) u/l; 54 (28-81) vs 30 (20-45) u/l; and 243 (177-415) vs 138 (116-175) mg/L, respectively (p < 0.01). Serum protein was however, significantly lower in samples from CCA patients [2.05 (1.2-4.4) vs 2.7 (1.3-4.3 mg/ml), p < 0.05]. For AST, ALP, plasma protein, and AP1, the AUCs of the ROCs (0.889, median (range): 316 (171-1,047) vs 80 (44-98) u/l; 54 (28-81) vs 30 (20-45) u/l; and 243 (177-415) vs 138 (116-175) mg/L, respectively (p < 0.01). Serum protein was however, significantly lower in samples from CCA patients [2.05 (1.2-4.4) vs 2.7 (1.3-4.3 mg/ml), p < 0.05]. For AST, ALP, plasma protein, and AP1, the AUCs of the ROCs (0.889,

Table 1. Phosphoproteins and Signaling Pathways Identified by Gel- and Solution-Based LC/MS-MS

<table>
<thead>
<tr>
<th>Pathway (Accession mapped IDs)</th>
<th>Protein</th>
<th>UniProt ID</th>
<th>Source</th>
<th>Protein expression</th>
</tr>
</thead>
<tbody>
<tr>
<td>PDGF signaling pathway (P00047)</td>
<td>p115</td>
<td>P98171</td>
<td>21B spot (gel-based)</td>
<td>Up</td>
</tr>
<tr>
<td></td>
<td>Serine/threonine-protein kinase mTOR</td>
<td>P42345</td>
<td>In solution</td>
<td>Down</td>
</tr>
<tr>
<td>FGF signaling pathway (P00021)</td>
<td>Chain A, Basic Fibroblast Growth Factor Complexed With Heparin Tetramer Fragment</td>
<td>P09038</td>
<td>21B spot (gel-based)</td>
<td>Up</td>
</tr>
<tr>
<td></td>
<td>Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit beta isoform</td>
<td>Q15173</td>
<td>In solution</td>
<td>Down</td>
</tr>
<tr>
<td></td>
<td>Serine/threonine-protein kinase mTOR</td>
<td>P42345</td>
<td>In solution</td>
<td>Down</td>
</tr>
<tr>
<td>EGF receptor signaling pathway (P00018)</td>
<td>Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit beta isoform</td>
<td>Q15173</td>
<td>In solution</td>
<td>Down</td>
</tr>
<tr>
<td>Dopaminergic receptor mediated signaling pathway (P05912)</td>
<td>FERM domain-containing protein 6</td>
<td>Q96NE9</td>
<td>In solution</td>
<td>Up</td>
</tr>
<tr>
<td>Nicotinic pharmacodynamics pathway (P06587)</td>
<td>FERM domain-containing protein 6</td>
<td>Q96NE9</td>
<td>In solution</td>
<td>Up</td>
</tr>
<tr>
<td>Interleukin signaling pathway (P00036)</td>
<td>Serine/threonine-protein kinase mTOR</td>
<td>P42345</td>
<td>In solution</td>
<td>Down</td>
</tr>
<tr>
<td>p53 pathway by glucose deprivation (P04397)</td>
<td>Serine/threonine-protein kinase mTOR</td>
<td>P42345</td>
<td>In solution</td>
<td>Down</td>
</tr>
<tr>
<td>R cell activation (P00010)</td>
<td>Tyrosine-protein kinase BTK</td>
<td>Q06187</td>
<td>In solution</td>
<td>Down</td>
</tr>
<tr>
<td>Hypoxia response via HIF activation (P00030)</td>
<td>Serine/threonine-protein kinase mTOR</td>
<td>P42345</td>
<td>In solution</td>
<td>Down</td>
</tr>
<tr>
<td>Wnt signaling pathway (P00057)</td>
<td>Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit beta isoform</td>
<td>Q15173</td>
<td>In solution</td>
<td>Down</td>
</tr>
</tbody>
</table>
Analysis of plasma phosphoproteome by gel-based LC-MS/MS

A total of 300 phosphoprotein spots were resolved (2DE), with two prominent 21 kDa up-regulated spots, namely 21A and 21B (Figure 1B). Results of the LC-MS/MS analysis revealed 98 and 64 identified proteins from the 21A and 21B spots. Analysis of the phosphorylation sites by PhosphoSitePlus identified 47 (47.9%) and 43 (67.2%) of the 21A and 21B spots as phosphoproteins, respectively. For the 21A spot, the number of phosphoproteins with serine-, threonine-, and tyrosine-phosphorylated sites were 40, 32, and 37, respectively. For the 21B spot, the number of phosphoproteins with serine-, threonine-, and tyrosine-phosphorylated sites were 36, 34, and 38, respectively.

Based on the MeV analysis results, cluster No.1 (out of the default 10 clusters) of the 21A spot contained five up-regulated phosphoproteins. These proteins were identified as trafficking protein particle complex subunit 5 (Q8IUR), tumor necrosis factor ligand superfamily member 9 (P41273), peripheral clock protein 2, MFS-type transporter C6orf192 (Q6NT16), and GREB1 protein isoform a (Q4ZG55) (Figure 2A). For the 21B spot, the three up-regulated phosphoproteins in cluster No.4 were identified as p115 (P98171), basic fibroblast growth factor complexed with heparin tetramer fragment (P09038), and crystal structure of human co-chaperone protein Hscb (Q8IWL3) (Figure 2B). Further analysis by the MeV program and statistical analysis by t-test suggested higher amount of the trafficking protein particle complex subunit 5 from the 21A spot in plasma of the CCA compared with non-CCA groups (Figure 3A). For the 21B spot, the amounts of p115 and in addition, hydrocephalus-inducing protein homolog isoform A were significantly higher in the CCA group (Figure 3B). Confirmation by KMC combined with t-test suggested only the trafficking protein particle complex subunit 5 and p115 as potential biomarkers for CCA. It is of interest to further investigate the involvement of these two proteins in cholangiocarcinogenesis in CCA cells. Results of PANTHER analysis also supported this finding, showing the possible association of these two up-regulated phosphoproteins (p115 and chain A basic fibroblast growth factor complexed with heparin tetramer fragment) with cholangiocarcinogenesis through cell signaling pathways (Table 1).

Analysis of phosphoproteome by solution-based LC-MS/MS

A total of 131 proteins were obtained from the LC-MS/MS analysis by DeCyder™ and MASCOT. Sixty (45.8%) proteins were identified as phosphoproteins with serine- (n=52), threonine- (n=39), and tyrosine- (n=49) phosphorylation. Results of the MeV-KMC analysis showed similar patterns of plasma phosphoproteins in CCA and non-CCA subjects (Figure 2C). Using average peak heights of all plasma samples in each group as a differential criterion, 31 and 29 phosphoproteins were classified as the up-and down-regulated phosphoproteins, respectively. Results of the gene ontology analysis revealed that most of these up- and down-regulated phosphoproteins were classified into three main groups based on functions as...
Differential Plasma Phosphoproteomes with Opisthorchis viverrini-Related Cholangiocarcinomas

those involved in i) biological processes (predominantly regulation process), ii) cellular components (predominantly cytoplasm), and iii) molecular function (predominantly binding proteins). The PANTHER analysis identified four possible phosphoproteins in cell signaling pathways, one up-regulated FERM domain-containing protein 6, and three down-regulated phosphoproteins (serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit beta isoform, serine/threonine-protein kinase mTOR, and tyrosine-protein kinase BTK) (Table 1). The roles of these phosphoproteins in cholangiocarcinogenesis remain to be elucidated. Results of the iPath analysis identified two phosphoproteins in metabolic pathways, i.e., V-type proton ATPase subunit C 1 of oxidative phosphorylation (up-regulated), and delta-1-pyrroline-5-carboxylate synthase isoform 1 of arginine and proline metabolism (down-regulated). None of the 60 phosphoproteins was identified as proteins involved in cell regulatory pathways and biosynthesis pathways of secondary metabolites.

Identification of plasma phosphoproteins as potential biomarkers of cholangiocarcinoma

Out of the sixty identified phosphoproteins by solution-based LC-MS/MS, the MeV-t-test results identified only 4 phosphoproteins with marked difference in amounts (peak heights) between plasma of CCA patients and non-CCA subjects. These included serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit beta isoform (Q15173), coiled-coil domain-containing protein 126 precursor (Q96EE4), transforming growth factor beta receptor II (70/80 kDa) isoform CRA_b, and FAM65A protein (Figure 3C). The sensitivity, specificity, PPV, and NPV of these proteins as biomarkers for CCA are summarized in Table 2.

In order to identify potential biomarkers for OV infection, the average peak heights from solution-based LC-MS/MS analysis of plasma from CCA patient (n=10), healthy subjects (n=5) and those with OV infection (n=5) was compared. Six patterns (A, B, C, D, E, and F) of peak heights were observed (Figure 4). However, only pattern D (consisting of 2 phosphoproteins) and F (consisting of 8 phosphoproteins) with a marked difference in average peak heights could discriminate individuals with OV infection from those with CCA (OV-related). Finally, results of both MeV-t-test and average peak height analysis identified only two phosphoproteins [coiled-coil domain-containing protein 126 precursor (Q96EE4) and serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit beta isoform (Q15173)] as potential biomarkers for OV infection.

Table 2. Solution-Based LC-MS/MS Analysis of Potential Phosphoproteins

<table>
<thead>
<tr>
<th>No</th>
<th>Name</th>
<th>UniPort ID</th>
<th>Sensitivity (%)</th>
<th>Specificity (%)</th>
<th>PPV</th>
<th>NPV</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Coiled-coil domain-containing protein 126 precursor</td>
<td>Q96EE4</td>
<td>90</td>
<td>60</td>
<td>0.69</td>
<td>0.86</td>
</tr>
<tr>
<td>2</td>
<td>FAM65A protein</td>
<td>-</td>
<td>90</td>
<td>30</td>
<td>0.56</td>
<td>0.75</td>
</tr>
<tr>
<td>3</td>
<td>Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit beta isoform</td>
<td>Q15173</td>
<td>60</td>
<td>90</td>
<td>0.86</td>
<td>0.96</td>
</tr>
<tr>
<td>4</td>
<td>Transforming growth factor, beta receptor II (70/80 kDa), isoform CRA_b</td>
<td>-</td>
<td>40</td>
<td>80</td>
<td>0.67</td>
<td>0.57</td>
</tr>
</tbody>
</table>

Table 3. Potential Biomarkers for CCA Diagnosis

<table>
<thead>
<tr>
<th>Test</th>
<th>Solution-based phosphoproteins</th>
<th>21A spot</th>
<th>21B spot</th>
</tr>
</thead>
<tbody>
<tr>
<td>MeV-KMC</td>
<td>Not significant</td>
<td>trafficking protein particle complex subunit 5 (Q8IU0R)</td>
<td>p115 (P98171)</td>
</tr>
<tr>
<td>MeV-t-test</td>
<td>(1) serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit beta isoform (Q15173)</td>
<td>(1) p115(P98171)</td>
<td>(2) hydrocephalus-inducing protein homolog isoform A</td>
</tr>
<tr>
<td></td>
<td>(2) coiled-coil domain-containing protein 126 precursor (Q96EE4)</td>
<td>(3) transforming growth factor beta receptor II (70/80kDa) isoform CRA_b</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(3) transforming growth factor beta receptor II (70/80kDa) isoform CRA_b</td>
<td>(4) FAM65A protein</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exclusive phosphoprotein was presented only in healthy subjects</td>
<td>1) biorientation of chromosomes in cell division protein 1-like</td>
<td>trafficking protein particle complex subunit 5 (Q8IU0R)</td>
<td>p115 (P98171)</td>
</tr>
<tr>
<td></td>
<td>2) serine/arginine repetitive matrix protein 3</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>3) Tubulin tyrosine ligase-like family, member</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
biomarkers for discrimination between OV infected subjects and CCA (OV-related) patients. In addition, the three phosphoproteins specifically expressed in CCA and OV were serine/arginine repetitive matrix protein 3 (A6NNA2), tubulin tyrosine ligase-like family member 6, and biorientation of chromosomes in cell division protein 1-like (Q8NFC6).

Discussion

Almost all laboratory tests and candidate biomarkers of CCA (plasma protein, AST, ALT, ALP, AP1, and CA 19-9) except AFP were shown in this study to be useful screening tests for CCA. In our previous study, a battery tests consisting of these tests were shown to produce a reliable diagnostic performance for CCA (Sriwanitchrak et al., 2011). However, these liver enzymes and tumor markers when used independently and separately have been reported to be relatively non-specific to CCA as the levels also increased in other diseases (Goni et al., 2013; Kunutsor et al., 2013; Zhang et al., 2013). Unexpectedly, such increase in the levels of these enzymes and tumor markers were not well correlated with the levels of plasma proteins. This suggests the possibility of other existing unidentified proteins as potential biomarkers of CCA.

Results of proteome analysis by gel-based and solution-based LC-MS/MS were inconsistent in identifying phosphoproteome and differential protein expression in CCA patients and non-CCA subjects (Table 3). For the gel-based LC-MS/MS analysis, up to 98 proteins were identified from a single plasma phosphoprotein spot. This high number of identified proteins could be due to their similarity of pI and molecular weight, as well as the resolution of SDS-PAGE. Using the MeV program with the application of KMC and t-test, two phosphoproteins from the 21A spot (trafficking protein particle complex subunit 5) and 21B (p115) were significantly up-regulated in CCA patients. The trafficking protein particle complex subunit 5 plays a role in vesicular transport from endoplasmic reticulum to Golgi, while the p115 plays a role in PDGF receptor signaling pathway (Sacher et al., 1998; Bai et al., 2011). Up-regulation of the first could contribute to the increase in the activity of the CCA cell in the transportation of the secreted and/or membrane proteins, or serve as an alternative protein trafficking pathway in CCA.

On the other hand, the up-regulation of p115 protein could enhance a signaling activity in the PI3K, JAK/STAT, and MEK/ARK pathways in CCA cells. With regard to the solution-based LC-MS/MS analysis, up to 98 proteins were identified from a single plasma phosphoprotein spot. This high number of identified proteins could be due to their similarity of pI and molecular weight, as well as the resolution of SDS-PAGE. Using the MeV program with the application of KMC and t-test, two phosphoproteins from the 21A spot (trafficking protein particle complex subunit 5) and 21B (p115) were significantly up-regulated in CCA patients. The trafficking protein particle complex subunit 5 plays a role in vesicular transport from endoplasmic reticulum to Golgi, while the p115 plays a role in PDGF receptor signaling pathway (Sacher et al., 1998; Bai et al., 2011). Up-regulation of the first could contribute to the increase in the activity of the CCA cell in the transportation of the secreted and/or membrane proteins, or serve as an alternative protein trafficking pathway in CCA.
phosphoproteins in CCA patients could imply that the chaperon protein was sufficiently expressed in CCA cell, allowing the cell to escape from apoptosis. Elucidation of the involvement of phosphoproteins in the complete network of signaling pathways in CCA was not possible in this study due to the limitation in the use of plasma as study sample. Approximately 4,000 phosphoproteins have been curated in the PhosphoSitePlus database (Yang et al., 2008); mostly intracellular proteins (Wang et al., 2011; Martins-de-Souza et al., 2012), with only small proportion of secreting and excreting phosphoproteins. It is estimated that about 30% of human proteins are phosphorylated proteins, but the exact proportion of the total plasma phosphoproteins remains unclear. Results of the present study showed that only a small amount (2-4%) of enriched phosphoproteins was obtained from plasma of both groups of subjects.

Since almost all CCA cases in Thailand are related to OV infection, the present study also investigated the biomarkers that would potentially discriminate CCA (OV-related) from OV infected patients. The analysis of patterns of average peak heights together with the MeV-t-test identified 10 phosphopeptides (peak height patterns D and F) and 4 phosphoproteins [FAM65A protein, coiled-coil domain containing protein 126 precursor (Q96EE4), serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit beta isoform (Q15173), and transforming growth factor beta receptor II (70/80 kDa) isoform CRA_b], respectively. Interestingly, both methods identified serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit beta isoform and coiled-coil domain containing protein 126 precursor phosphoproteins as potential biomarkers of CCA.

In conclusion, the present study identified several potential biomarkers of CCA (OV-related) and OV infection (Table 3). Serine/arginine repetitive matrix protein 3 (A6NNA2), tubulin tyrosine ligase-like family, member 6, and biorientation of chromosomes in cell division protein 1-like (QSNFC6) were identified as potential biomarkers for the screening of healthy subjects from CCA and OV infected patients (Figure 5). On the other hand, coiled-coil domain-containing protein 126 precursor (Q96EE4) and serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit beta isoform (Q15173) were identified as potential biomarkers for the differential diagnosis of CCA (OV-related) and OV infected patients. Additionally, the down-regulated serine/threonine-protein kinase mTOR could be a potential drug target for CCA (Mooltithya et al., 2014). Validation of diagnostic performance of these biomarkers in a large number of patients (CCA and OV infected) is required before a large scale clinical application of these proteins as a screening tool for CCA is to be adopted. Nevertheless, application of these phosphoproteins as diagnostic or prognostic biomarkers of CCA and OV may be limited by their relatively high cost and test complexity. It is likely that a combination of biomarkers together with liver function tests as a battery of tests, rather than a single test, would be a more reliable screening tool for CCA (Malagunera et al., 2013).

Acknowledgements

This study was supported by the National Research University Project (NRU) of Thailand Office of Higher Education Commission, Ministry of Education of Thailand and Thammasat University (Excellence Center in Pharmacology and Molecular Biology of Malaria and Cholangiocarcinoma).

References

Liang D, Zeng Q, Xu Z, et al (2014). BAFF activates Erk1/2 promoting cell proliferation and survival by Ca2+-CaMKII-


